March 8 (Reuters) - Amylyx Pharmaceuticals ( AMLX )
said on Friday its drug to treat a neurological disorder called
ALS, or amyotrophic lateral sclerosis, failed to meet the main
goal in a late-stage confirmatory study.
The company said its plans for the drug may include
voluntarily withdrawing it from the market.
(Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj
Kalluvila)